GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report)'s stock price passed below its fifty day moving average during trading on Wednesday. The stock has a fifty day moving average of $3.44 and traded as low as $3.36. GoodRx shares last traded at $3.36, with a volume of 658,734 shares.
Wall Street Analysts Forecast Growth
GDRX has been the subject of several recent research reports. Barclays raised their target price on shares of GoodRx from $3.00 to $4.00 and gave the stock an "underweight" rating in a report on Thursday, August 20th. Wall Street Zen upgraded shares of GoodRx from a "hold" rating to a "buy" rating in a research report on Saturday, August 15th. Wells Fargo & Company upped their price target on shares of GoodRx from $3.50 to $5.00 and gave the company an "overweight" rating in a report on Friday, August 7th. TD Cowen increased their price target on GoodRx from $4.00 to $5.00 and gave the stock a "buy" rating in a research report on Tuesday, August 11th. Finally, Weiss Ratings reaffirmed a "sell (d+)" rating on shares of GoodRx in a research report on Wednesday, November 4th. Four equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $4.15.
Get Our Latest Analysis on GoodRx
GoodRx Price Performance
The company has a market capitalization of $1.15 billion, a price-to-earnings ratio of 84.02 and a beta of 1.66. The stock has a fifty day simple moving average of $3.44 and a 200-day simple moving average of $2.89. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.38 and a quick ratio of 1.38.
Insider Activity at GoodRx
In other news, major shareholder Francisco Partners Iv, L.P. sold 1,296,177 shares of GoodRx stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $3.50, for a total transaction of $4,536,619.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders have sold 1,841,761 shares of company stock worth $6,432,783. 5.87% of the stock is owned by company insiders.
Institutional Trading of GoodRx
Hedge funds have recently added to or reduced their stakes in the company. Essential Partners LLC grew its position in GoodRx by 375.4% during the first quarter. Essential Partners LLC now owns 14,304 shares of the company's stock valued at $28,000 after buying an additional 11,295 shares during the period. Headlands Technologies LLC purchased a new position in GoodRx in the second quarter valued at $30,000. Focus Advisor Solutions LLC acquired a new position in shares of GoodRx in the third quarter worth about $33,000. R Squared Ltd acquired a new position in shares of GoodRx in the third quarter worth about $36,000. Finally, Amundi acquired a new position in shares of GoodRx in the first quarter worth about $37,000. 63.77% of the stock is owned by hedge funds and other institutional investors.
About GoodRx
(
Get Free Report)
GoodRx Holdings, Inc. operates a digital healthcare platform that helps consumers in the United States compare prescription medication prices at pharmacies. Its website and mobile app provide free price comparisons and discounts that consumers can use when paying for eligible prescriptions. The company also offers subscription services, including GoodRx Gold, and provides access to telehealth and other care services through GoodRx Care. Its platform connects consumers with pharmacies and healthcare providers, while its services for pharmaceutical companies include programs that help make medications and savings offers available to patients.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider GoodRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GoodRx wasn't on the list.
While GoodRx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.